Open access
Open access
Powered by Google Translator Translator

Daily Archives: October 19, 2021

Long-term consequences of the misuse of ivermectin data.

19 Oct, 2021 | 09:56h | UTC

Long-term consequences of the misuse of ivermectin data – The Lancet Infectious Diseases

Related:

Ivermectin: How false science created a Covid ‘miracle’ drug.

Fraudulent ivermectin studies open up new battleground between science and misinformation.

The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.

Ivermectin: Cochrane’s most talked about review so far, ever. Why?

Flawed ivermectin preprint highlights challenges of COVID drug studies.

Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19.

Why was a major study on ivermectin for covid-19 just retracted?

RCT: Ivermectin does not prevent hospitalizations in patients with COVID-19.

Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”.

Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.

Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials

RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19

 

Commentary on Twitter

 

RECOVERY Trial: In patients admitted to hospital with COVID-19, Colchicine did not reduce 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.

19 Oct, 2021 | 10:14h | UTC

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – The Lancet Respiratory Medicine

Related:

[Preprint] PRINCIPLE RCT: Colchicine does not improve time to recovery in outpatients with Covid-19 at higher risk of complications.

COLCORONA RCT: Colchicine for community-treated patients with COVID-19 – findings suggest it may lower death and hospital admission rates, but further studies are required.

[Preprint] RECOVERY Trial: Colchicine does not improve outcomes in patients admitted to hospital with COVID-19.

 

Systematic Review: Colchicine for the treatment of COVID‐19 – not beneficial for hospitalized patients; inconclusive evidence for the treatment of non-hospitalized patients, “probably slightly reduces the need for hospitalization or death within 28 days compared to placebo”.

19 Oct, 2021 | 10:13h | UTC

Colchicine for the treatment of COVID‐19 – Cochrane Library

Related:

[Preprint] PRINCIPLE RCT: Colchicine does not improve time to recovery in outpatients with Covid-19 at higher risk of complications.

COLCORONA RCT: Colchicine for community-treated patients with COVID-19 – findings suggest it may lower death and hospital admission rates, but further studies are required.

[Preprint] RECOVERY Trial: Colchicine does not improve outcomes in patients admitted to hospital with COVID-19.

 

Commentary on Twitter

 

China’s COVID vaccines have been crucial — now immunity is waning.

19 Oct, 2021 | 09:53h | UTC

China’s COVID vaccines have been crucial — now immunity is waning – Nature

Related:

[Preprint] Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – “Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%”.

Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high.

Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

Editorial | Covid-19 vaccination: evidence of waning immunity is overstated.

COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

COVID vaccine effects wane over time but still prevent death and severe illness.

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

 

BJS commission on surgery and perioperative care post-COVID-19.

19 Oct, 2021 | 09:52h | UTC

BJS commission on surgery and perioperative care post-COVID-19 – British Journal of Surgery

Related: Cohort Study: Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumor types in 61 countries.

 

Commentary on Twitter

 

Editorial: Preparing for “Disease X”.

19 Oct, 2021 | 09:54h | UTC

Preparing for “Disease X” – Science

 

Another observational study suggests Rivaroxaban is associated with higher rates of gastrointestinal bleeding than other direct oral anticoagulants.

19 Oct, 2021 | 09:47h | UTC

Rivaroxaban Is Associated with Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants: A Nationwide Propensity Score–Weighted Study – Annals of Internal Medicine (link to abstract – $ for full-text)

Commentary: Rivaroxaban Again Linked to More Bleeding vs Other DOACs – TCTMD

Related: Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study – Gastroenterology

 

Commentary on Twitter

 

Cluster RCT: An exercise intervention may improve academic achievement among children.

19 Oct, 2021 | 09:45h | UTC

Exercise Intervention for Academic Achievement Among Children: A Randomized Controlled Trial – Pediatrics

 

Commentary on Twitter

 

Guideline: Management of anticoagulants and antiplatelet agents in cutaneous surgery.

19 Oct, 2021 | 09:50h | UTC

S3 guideline: Management of anticoagulants and antiplatelet agents in cutaneous surgery – Journal of the German Society of Dermatology

 

Systematic Review: Calcium channel blockers versus other classes of drugs for hypertension – “there is moderate certainty evidence that diuretics reduce major cardiovascular events and congestive heart failure more than CCBs”.

19 Oct, 2021 | 08:56h | UTC

Summary: Calcium channel blockers versus other classes of drugs for hypertension – Cochrane Library

Original Study: Calcium channel blockers versus other classes of drugs for hypertension – Cochrane Library

 

Commentary on Twitter

 

Urolithiasis: ED presentations, evaluation, management, and disposition.

19 Oct, 2021 | 08:53h | UTC

Urolithiasis: ED Presentations, Evaluation, Management, and Disposition – emDocs

 

Podcast: Diagnosis and treatment of Celiac Disease.

19 Oct, 2021 | 08:54h | UTC

#300 Celiac Disease with Dr. Amy Oxentenko – The Curbsiders

 

Preoperative hypertension: perioperative implications and management.

19 Oct, 2021 | 08:51h | UTC

Preoperative hypertension: perioperative implications and management – BJA Education

 

Bioethics | The Reluctant Patient and the Insistent Doctor.

19 Oct, 2021 | 08:50h | UTC

The Reluctant Patient and the Insistent Doctor – The American Journal of Medicine

 

Review: Wilms Tumor.

19 Oct, 2021 | 08:44h | UTC

Wilms tumour – Nature Reviews Disease Primers (free for a limited period)

Infographic: Wilms tumour

 

Commentary on Twitter

 

Opinion | Multi-cancer screening tests: communicating about risks should be prioritized.

19 Oct, 2021 | 08:49h | UTC

Multi-cancer screening tests: communicating about risks should be prioritized. – The American Journal of Medicine

 

Review: Stroke prevention after cryptogenic stroke.

19 Oct, 2021 | 08:46h | UTC

Stroke Prevention After Cryptogenic Stroke – Current Cardiology Reports

Related:

2 recent meta-analysis highlight the benefits of short term (30 days) dual antiplatelet therapy with aspirin + clopidogrel in patients within 24 hours of high-risk transient ischemic attack or mild-moderate ischemic stroke.

Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke – The BMJ

Stroke and transient ischaemic attack in over 16s: diagnosis and initial management – National Institute for Health and Care Excellence

Canadian Stroke Best Practice Recommendations for Acute Stroke Management

 

M-A: Risk factors for invasive candida infection in critically ill patients – The risk factors associated with the highest risk for ICI were broad spectrum antibiotics (OR 5.6), blood transfusion (OR 4.9), Candida colonization (OR 4.7), central venous catheter (OR 4.7) and total parenteral nutrition (OR 4.6).

19 Oct, 2021 | 08:47h | UTC

Risk factors for invasive candida infection in critically ill patients – a systematic review and meta-analysis – Chest

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.